AMGN

In the past six months, Amgen's stock has experienced several notable events. As of May 5, 2026, the share price was $329.59, representing an increase of 21.87% over the past year. On May 1, 2026, Amgen's shares fell 5% despite reporting revenue and earnings growth, partly attributed to analyst downgrades, elevated net debt, and insider selling. Competition has intensified for key Amgen drugs, with sales declines in Prolia, Xgeva, and Enbrel. Amgen also faced clinical setbacks, halting trials for several drugs due to failed efficacy tests or safety concerns. Despite these challenges, Amgen's Q1 2026 results showed growth in key areas, and the company announced an additional investment in its Puerto Rico manufacturing facility.